Insulin Resistance in Multiple System Atrophy
University Hospital, Bordeaux
124 participants
Oct 28, 2020
INTERVENTIONAL
Conditions
Summary
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.
Eligibility
Inclusion Criteria10
- Patients :
- Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al., 2008).
- Age > 30
- Written informed consent
- Patient covered by the national health system
- Controls:
- Patients not suffering from a neurologic disorder
- Age > 30
- Written informed consent
- Patient covered by the national health system
Exclusion Criteria9
- For patients and controls:
- Presence of a diabetes
- Treatment with corticosteroids, estrogen, atypical antipsychotics, and anti-retroviral agents
- Patient under tutelage
- Patient unable to give consent
- Any other neurologic disorder
- Pregnancy and breastfeeding
- MOCA ≤21
- Contraindication to perform an MRI
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
Optional blood sampling for the constitution of a biological collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04250493